资讯
There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...
Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...
Moderna Inc. shares declined after the company’s first-quarter vaccine sales missed estimates and it disclosed a delay in the ...
“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...
15 小时on MSN
The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...
Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...
FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.
The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.
From STAT’s Jason Mast: Moderna said this morning in its earnings report it planned to cut costs by around $1.5 billion by ...
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...
In an interview with Dr. Phil, the health secretary offered false information about vaccine oversight and revealed a lack of ...
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果